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PAIN SENSITIVITY: SEX DIFFERENCES, GENETICS AND THE ASSOCIATION
WITH CHRONIC JOINT PAIN
M. de Kruijf, M.J. Peters, A. Hofman, F. Rivadeneira, S.M. Bierma-
Zeinstra, F.J. Huijgen, A.G. Uitterlinden, J.B. van Meurs. Erasmus MC,
Rotterdam, Netherlands
Purpose: Chronic musculoskeletal pain (CMP) is very common in the
population, with osteoarthritis being the most eminent underlying
disease. The aetiology of CMP is complex with both genetics and envi-
ronment playing a role. One of the characteristics determining the
development of CMP is a person's sensitivity to pain. We therefore aim to
elucidate the determinants of pain sensitivity in the general population
and in chronic pain.
Methods: Until the summer of 2011, for 754 participants of the Rotterdam
Study, pain sensitivity was determined by measuring heat pain thresholds
using a thermo-sensory analyzer (TSA II, Medoc Advanced Medical
Systems, Durham, NC). Forty-ﬁve participants were excluded due to
personal or technical problemswith the test. Participants completed a pain
homunculus, inwhich they draw circles around joints where they had pain
for more than half of the days, in the last six weeks. Cox regression was
used to evaluate the relationship between heat pain thresholds and
baseline characteristics (age, gender, BMI), and the associationwith having
chronic pain in more than 2 joints in a case-control setting. In an extensive
literature search, we found 44 previously described genes of which 136
single nucleotide polymorphisms (SNPs) were possibly associated with
pain phenotypes. Using linear regression, we tested the association
between these SNPs and the heat pain thresholds in 558 participants for
which genetic data was available.
Results: In the 709 participants, the mean age was 71.7 (65.9-92.9), 52.9%
was female. Themeanpain threshold ofwomenwas on average 2.0oC lower
compared tomen (p¼1.7x10-14). Heat pain thresholdwas not related to age
or BMI. Whenwe compared participants without joint pain and those with
pain inmore than 2 joints, we observed that the participantswith pain have
an on average 1.3 oC higher mean pain threshold temperature (p¼0.03). Of
the 44 candidate gene loci, the SNP rs8192619 in the TAAR1 gene (trace
amine associated receptor 1) at chromosome 6 was the most associated
with the pain threshold temperature (p¼0.02). Carriers of the minor A-
allele (frequency: 5%) had 1.1oC lower mean heat pain threshold. This
ﬁnding is in line with the corresponding literature, in which the minor A-
allele was associated with a higher risk for ﬁbromyalgia.
Conclusions: We found a difference in pain sensitivity between sexes,
with females being more sensitive to pain. We demonstrated that the
mean pain threshold is higher in persons suffering from chronic joint pain,
indicating the activation of the pain inhibitory mechanisms in these
individuals. We found genetic variation in the TAAR1 gene to be associated
with pain sensitivity. This is an interesting locus because it encodes
a receptor that regulates monoamine levels in the brain and is implicated
in the functional regulation of the dopamine system. Heat pain threshold
measurements are still ongoing to increase power. Replication in our own
and other cohorts is needed to verify our ﬁndings.
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THE RELATIONSHIP BETWEEN NEUROPATHIC PAIN SYMPTOMS ON THE
MODIFIED PAIN DETECT AND SIGNS OF CENTRAL SENSITIZATION IN
KNEE OSTEOARTHRITIS
J. Hochman 1, J. Elkayam1, L. Gagliese 2, A. Davis 3, G. Hawker 1. 1Women's
Coll. Hosp., Toronto, ON, Canada; 2Univ. Hlth.Network, Toronto, ON,
Canada; 3 Toronto Western Res. Inst., Toronto, ON, Canada
Purpose: Central sensitization may contribute to pain in a subset of people
with knee OA and present with a distinct clinical phenotype including
neuropathic-like symptoms and sensory abnormalities. A neuropathic pain
(NP) questionnaire modiﬁed for use in knee OA, the modiﬁed painDETECT
(mPD-Q), may aid the identiﬁcation of central sensitization in this pop-
ulation. The aim of this novel study was to assess the relationship between
mPD-Q scores and signs of central sensitization, assessed using a quanti-
tative sensory testing (QST) protocol, in adults with chronic knee OA.Methods: Eligible participants had chronic, symptomatic, knee OA,
without other pain or neurological conditions. Age and gender matched
reference data was obtained from controls, enabling identiﬁcation of
sensory abnormalities among individual participants. Prior to QST, data
was collected on NP symptoms (mPD-Q) for each knee, sociodemographic
factors, BMI, OA duration and severity (WOMAC), pain intensity (Von Korff
Chronic Pain Grade, CPG, pain intensity subscale), depressive symptoms
(Centre for Epidemiologic Studies Depression Scale, CES-D), and pain
catastrophizing (pain catastrophizing scale, PCS). The standardized/
comprehensive QST protocol, developed by the German Research Network
on Neuropathic Pain (DFNS), was conducted on the medial aspect of all
eligible knees. QST signs of central sensitization were deﬁned as:
mechanical hyperalgesia and/or enhanced temporal summation and /or
allodynia. Abnormal sensation was deﬁned as QST ﬁndings >2 standard
deviations above or below the mean of controls. Generalized estimating
equation modeling was used to examine the relationship between the
presence of central sensitization (yes/no) and mPD-Q scores (above or
below the median) by knees.
Results: The majority of the 36 participants were female (83.3%) and
Caucasian (83.3%), aged (SD) 60.7 (6.8) years, with a high median (min,
max) BMI of 28.2 (19.5, 62.3). Mean (SD) duration of knee symptoms and
time since knee OA diagnosis were 13.6 (13.2) years and 7.4 (10.0) years,
respectively. Mean (SD) severity of OA was moderate: WOMAC total was
38.7/96 (18.5), CPG score was 52.0/100 (19.8). Among the 36 study
participants, 57 knees were painful and eligible for participation. Median
mPD-Q score among all knees was 9 (range 0-33). 45.6% of assessed knees
had  1 sign of central sensitization in order of frequency: mechanical
hyperalgesia (36.8%), enhanced temporal summation (10.5%), and allody-
nia (5.3%). Controlling for age, individuals with higher mPD-Q scores (
the median of 9.0) had a signiﬁcantly higher odds of meeting our criteria
for central sensitization (adjusted OR ¼ 3.85; 95% CI, 1.16-12.7, p ¼0.027).
Additional adjustment for pain catastrophizing, pain intensity, or
depressed mood did not attenuate this relationship.
Conclusions: Among a sample of adults with chronic, painful knee OA,
higher scores on the mPD-Q were associated with greater odds of having
one or more sign of central sensitization on QST. Thus, the mPD-Q may aid
the identiﬁcation of central sensitization in adults with chronic knee OA.
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ANALYSIS OF CIRCULATING IMMUNE COMPLEXES CONTAINING PAIN-
ASSOCIATED MOLECULES IN PATIENTS WITH KNEE OSTEOARTHRITIS:
FROM THE LABORATORY TO THE CLINIC
Y. Savitskaya, L. Ramos, C. Duarte, R. Tellez, E. Estrada, E. Morales, N.
Marin, F. Cruz, A. Almazan, C. Ibarra. Natl. Inst. of Rehabilitation, Mexico,
Mexico
Purpose: Today’s leading laboratory researchers, pharmacy and biotech
decision-makers, technology companies and clinicians are focusing on the
uses of biomarkers in the ﬁeld of osteoarthritis research. Osteoarthritis of
the knee (kOA) has in the past been considered a predominately degen-
erative joint disease, affecting more people than any other arthritis. In kOA
disease, pathogenic pain-associated molecules are used for development
of diagnostic criteria, monitoring of disease activity, and prognosis. As
such, the body has many pain messengers, receptors and neural pathways
to sense that information. Analysis of circulating immune complexes (CICs)
produced during an immune response may be useful in elucidating some
aspects of kOA process. To investigate the presence of immune complexes
containing pain-associated molecules such as interleukin 6 (IL-6), inter-
leukin 18 (IL-18), angiotensin-converting enzyme (ACE), prostaglandin E2
(PGE2) in the peripheral blood sera of kOA patients and to evaluate their
potential as markers of kOA pathogenesis. This knowledge increases he
quality of medicine and surgery.
Methods: Circulating biomarker-Ig immune complexes were measured in
serum samples from 54 patients with kOA and from 54 healthy controls
using a novel ELISA (INR, Mexico). kOA severity as deﬁned by increasing
Kellgren & Lawrence (KL) grade. Pain was measured using a visual
analogue scale (VAS, 0-100 mm). kOA biopsies were obtained at arthros-
copy. Apoptosis was assessed using Caspase-Glo 3/7 assay.
Results:We applied our strategy to the analysis of CICs in kOA patients and
healthy controls. Our technique for CICs analysis uses routine clinical
